The whey acidic protein ( WAP ) promoter is known to be active in pregnant and lactating mammary epithelial cells as well as mammary tumors of mice. Here we show that a proximal fragment of the murine WAP promoter, including most elements postulated as being responsible for mammary -specific regulation, confers mammary -specific expression upon a marker gene in transgenic mice even though the distal promoter region, known to be important for rat WAP promoter activity, is lacking. The relatively small size of this fragment allows its insertion into a murine leukemia virus -based retroviral vector in place of the viral promoter. Infection of a number of established human mammary and nonmammary cell lines with such a retroviral vector revealed that the WAP promoter was limited in its activity to mammary tumor cell lines. Expression in tumorigenic mammary cells was even more pronounced when these cells were introduced into the mammary fat pads of mice. This is the first demonstration that the WAP promoter is active in human mammary cells and mammary tumor cells in general, and suggests that the extended proximal WAP promoter may be useful for directing therapeutic gene expression to human mammary tumors.
T he ability to target gene expression is an important facet of gene therapy, both with respect to efficacy and safety.
1,2 Expression targeting to breast cancer cells can be achieved using a number of candidate promoters, isolated from genes that are specifically or preferentially active in these cells.
The whey acidic protein (WAP ) promoter was originally cloned from the genome of rodents and has been used in the context of various transgenes to direct expression of linked sequences preferentially to the mammary gland of pregnant and lactating mice ( reviewed by Hennighausen 3 ). In addition to rats and mice, 4 WAP gene homologs have been found in rabbits 5 and, more recently, in pigs and camels, 6, 7 but a human homolog has yet to be identified. Nevertheless, it may be expected that the underlying regulatory mechanisms controlling the expression of many, if not all, milk genes are similar among all mammals. The WAP promoter has been arbitrarily divided into two regions, one proximal and one distal to the transcription initiation site. The proximal region ( À 50 to À 150) is equivalent to a DNase hypersensitive site (HSSII ) identified in the rat WAP promoter, whereas the distal region ( À 700 to À 800 in the rat promoter ) colocalises with a second hypersensitive site (HSSI ). 8 Both of these regions contain consensus binding sequences for a number of transcription factors that have been associated with mediation of mammary -specific gene expression ( Fig 1) .
Li and Rosen 8 have extensively studied the proximal region of the rat WAP promoter in transgenic mice. This region contains a -interferon -activating sequence (GAS ), with a consensus binding site sequence of TTCNNNGAA for mammary gland factor (also known as signal transducer and activator of transcription or STAT5 ), which mediates prolactin induction of milk protein gene expression ( Fig 1 ) . 9 Although STAT5 proteins and GAS sites are ubiquitously found, milk gene expression is confined to mammary tissues. Thus, additional factors must be involved. This is supported by the finding that although mutation of the WAP distal GAS site dramatically reduces transgene expression in vivo, it does not alter the pattern of tissue -specific expression. 8 The promoter distal region contains binding sites for at least two other candidate factors. There are two NF1 sites, one a complete palindrome and the other a half -site. The NF1 transcription factor was originally considered to be ubiquitously active; however, the presence of at least four NF1 genes as well as differential splicing gives rise to cell and tissue type -specific forms of this factor. 10 Mutation of the palindromic NF1 site, either alone or in combination with the half -site, eliminates WAP expression in the mammary glands of transgenic mice and even mutation of the half -site alone reduces expression levels by 90%. This clearly demonstrates that NF1 plays a key role in the in vivo regulation of WAP promoter activity. 8 Another candidate factor is the glucocorticoid receptor ( GR ) complex. The distal region of the WAP promoter carries at least two glucocorticoid response elements (GREs). This region is able to confer glucocorticoid inducibility upon heterologous promoters and has been shown to become DNase I-hypersensitive after addition of the hormone. 11 The idea that mammary specificity results from the cooperative interactions of some of these factors gained support from the finding that the GR can act as a transcriptional coactivator of STAT5 and enhance STAT5 -dependent transcription. 12 Although the STAT5 protein can form a complex with the GR in many cell types, lactogenic hormone treatment of mammary cells results in the GR associating with the STAT5 that is bound to DNA. 13 Even though the distal WAP sequences seem to be absolutely required for mammary -specific expression from the rat WAP promoter, 11 both the rat and mouse promoter regions carry another similar, but more promoter-proximal, region. We have previously shown that the distal region of the mouse WAP promoter is not required for pregnancydependent mammary expression, although it may play a role in regulating the level of expression. 14 The proximal region of both promoters also carries, in addition to a GAS site and sites for the GR and NF1 factors, a whey protein promoter consensus sequence, 15 homologous to a binding site for a nuclear factor located in the ratlactalbumin gene, as well as the binding site for a putative mammary cell activating factor, MAF, 16 to which Ets binds ( Fig 1) . The binding of members of the Ets family of DNA binding proteins is important for hormoneindependent promoter function 17 but also appears to play a critical role in the activation of the WAP promoter during pregnancy but not lactation. 18 Interestingly, analysis of mice carrying a transgene (WAP1 -hGH ), which lacks this Ets binding site, reveals pregnancy-dependent but temporally disturbed mammary gene expression and no expression during lactation. 14 Thus, it appears that the regulation of WAP gene expression is determined by the cooperative interaction of a number of transcription factors with several binding sites, all located in close proximity to facilitate interactions, constituting two composite response elements ( distal and proximal ) for lactogenic activation of promoter activity, though the functionality of these two may differ from species to species.
8,19
Figure 1 Schematic representation of the WAP promoter. Some of the major binding sites for factors involved in regulation of expression from the mouse and rat WAP promoters are indicated. The WAP promoter is divided into two regions of similarity -the proximal and the distal regions.
Cancer Gene Therapy WAP promoter targets human mammary tumor cells F Ö ztü rk -Winder et al An additional GAS site is located downstream of the proximal element and just upstream of the transcriptional start site (Fig 1 ) . In combination with an NF1 half -site and a GRE, this GAS site is associated with pregnancydependent mammary expression of a linked transgene ( WAP1 -hGH ) in vivo.
14 In light of the observation that the distal element of the rat WAP promoter fragment is essential for tissue -specific expression in mice 11 and yet a minimal mouse WAP promoter fragment containing only part of the proximal region is able to give a low -level but pregnancydependent expression, we investigated further the expression from the mouse WAP promoter containing the complete promoter proximal region but lacking the distal region.
Here we demonstrate that a 405 -bp fragment of the murine WAP promoter, including the complete proximal promoter, gives high -level mammary -specific expression of a linked gene in transgenic mice. The 405 -bp fragment was also cloned into a promoter conversion (ProCon) retroviral vector 20, 21 and used to transduce mammary tumor -derived cells of human and murine origin. This type of vector may allow promoter specificity to be maintained, in contrast to more commonly used retroviral vector configurations. 2 Expression from the WAP promoter was obtained in mammary cells transduced with the vector, but only when they were grown in collagen matrices and stimulated with pregnancy hormones. In contrast, the WAP promoter was not active in transduced human tumor cells of nonmammary origin. The specificity of expression for human tumor cells of mammary origin was even more pronounced when the infected cells were reimplanted into the mammary fat pad of mice. Thus, a relatively small fragment of the mouse WAP promoter containing the promoter proximal region is able to mediate mammary specificity and also mammary tumor specificity, also when it is inserted into a retroviral vector and subsequently used to infect human mammary tumor cells.
Materials and methods

WAP3 -hGH transgenic mice
The WAP3 -hGH transgene was derived from the previously described WAP2 -hGH transgene 14 by digestion with XhoI and carries 450 bp of the WAP promoter, including the previously identified NRE, 22, 23 coupled to the human growth hormone gene. The plasmid was linearized by digestion with EcoRI, purified, and used to produce transgenic mice as previously described. 24 The animal studies were conducted in accordance with the principles and procedures outlined in the ''Guidelines for Care and Use of Experimental Animals'' and according to the Austrian Animal Experimentation Laws.
Southern blot analysis of WAP3 -hGH transgenic mice
Genomic DNA was prepared and 20 g was digested with BglII, which cleaves once within the transgene, and separated on a 0.8% agarose gel. After transfer to a ZetaProbe membrane (Bio -Rad, Hercules, CA ), the DNA was hybridized with a 0.9 -kb 32 P-labeled hGH PvuII /BglII fragment. This probe hybridizes to a 5.9 -kb -specific hGH fragment. Densitometric analysis of the hybridization signal was performed using a Molecular Dynamics Storm Imager.
Reverse transcription polymerase chain reaction ( RT -PCR ) analysis of expression in transgenic mice
RNA was prepared from the mammary glands of transgenic mice by the guanidium isothiocyanate method and 1 g used for RT-PCR analysis. In order to detect hGHspecific transcripts, the primer pairs hGHex2c (5 0 -TCC-CTGCTCCTGGCTTTT-3 0 ) and hgHex5 ( 5 0 -ACAGAGC-GGCACTGCACGAT-3 0 ) were used. Each cycle consisted of a denaturation step (948C for 30 seconds ), annealing at 558C for 30 seconds, and elongation at 688C for 45 seconds for 10 cycles. An hGH -indicative fragment of 518 bp is expected. The quality of the RNA was also examined by RT-PCR analysis using primers recognizing the murine GAPDH (gap: 5 0 -TTGTGCAGTGCCAGCCT-CGT-3 0 and gapc: 5 0 -GGATGACCTTGCCCACAGCCT-3 0 ) and the same conditions as for hGH except an annealing temperature of 578C. The expected GAPDHspecific fragment size is 690 bp.
Real -time RT -PCR assay conditions and data analysis
The primer and probe sequences for the two real -time RT-PCR assays (hGH for promoter expression and rRNA for cell number estimation ) were designed with Primer Express software ( Applied Biosystems, Foster City, CA ).
The hGH assay consists of the primers hGH228f (5 0 -CTATTCCGACACCCTCCAACA -3 0 ) and hGH449r (5 0 -CATCTTCCAGCCTCCCCAT-3 0 ) and the probe hGH266v ( 5 0 -VIC -AAATCCAACCTAGAGCTGCTCCGCAT-CT-TAMRA -3 0 ). In order to prevent amplification of genomic DNA, the forward primer was placed in exon 3, whereas the probe was placed on the border of exons 3 and 4 and the reverse primer was placed on the border of exons 4 and 5.
The rRNA assay 25 consists of the primers rRNA343f (5 0 -CCATCGAACGTC TGCCCTA -3 0 ) and rRNA409r ( 5 0 -TCACCCGTGGTCACCATG -3 0 ) and the probe rRNA370p (5 0 -FAM -CGATGGTGGTCGCCGTGCCTA -TAMRA-3 0 ). All probes are phosphorylated at the 3 0 -OH to prevent elongation during the PCR. All oligonucleotides were highperformance liquid chromatography -purified and obtained from Applied Biosystems ( Weiterstadt, Germany ).
The 25-l RT-PCR mixtures contained 10 l of AMV /Tfl 5Â reaction buffer ( Access RT-PCR System; Promega, Mannheim, Germany ), 3 mM MgSO 4 , 200 M dATP, dCTP, dGTP, dTTP, 300 nM of each primer, 200 nM fluorogenic probe, 5 U of AMV reverse transcriptase, 5 U of Tfl DNA polymerase, and 5 l of the sample or RNA standard. After a reverse transcription step of 45 minutes at 488C followed by a denaturation step ( 2 minutes at 958C ), amplification was performed with 45 cycles of 15 seconds at 958C and 60 seconds at 608C. Reverse transcription and amplification were performed in an ABI Prism 1 7700 Sequence Detection System (Applied Biosystems ). The detected fluorescence signals are analysed using the Sequence Detection Software Version 1.6.3 (Applied Biosystems ).
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The relative hGH expression was estimated using the ÁÁC T method. In brief, the hGH expression per sample was normalized to the amount of cells using the difference of C T values obtained in the rRNA and the hGH assay ( ÁC T ). The ÁC T value is inversely proportional to the relative hGH expression per sample. The highest ÁC T value reflects the sample with the lowest hGH expression per cell. This hGH expression was arbitrarily set as 1. In order to compare the hGH expression in the different samples, the highest ÁC T value (sample with the lowest hGH expression ) was subtracted from the calculated ÁC T value of each sample. The obtained ÁÁC T values reflect a PCR cycle number, which can be used to calculated the relative hGH expression ( relative to the sample with the lowest hGH expression ) using the equation: 2eÁÁC T .
Construction of the WAP ProCon retroviral vector
The WAP promoter-carrying ProCon vector is based upon the murine leukemia virus (MLV )-derived BAG retroviral vector and carries a -galactosidase ( -gal ) gene expressed from the MLV promoter as well as a neomycin gene expressed from the SV40 promoter. 26 Even though the titers obtained with this vector are lower than those from more contemporary vectors, the presence of a prokaryotic origin of replication in the vector allows facile recloning of integrated proviruses for later molecular characterization.
The WAP promoter from the previously described plasmid WAP2 -hGH 14 was amplified by PCR using the primers R1 (5 0 -CTGCCTCTCCCCTCAGGACACA -3 0 ) and R2 (5 0 -AACCGCGGCCAGGAGAAGTCACCCTCAG -3 0 ), denatured at 948C for 1 minute, annealed at 568C for 2 minutes, and elongated at 728C for 3 minutes. The PCR fragment was digested with SacII and MluI and inserted into the plasmid pCon 6. 27 Then the BamHI fragment of pBAGN was inserted into pCon 6 to recreate a complete provirus, as previously described. 21, 27 Cell lines NIH3T3 mouse fibroblasts cells 28 and the derived retroviral packaging cell line, PA317, 29 as well as feline kidney epithelial cells ( CrFK ), 30 the human bladder carcinomaderived cell line EJ, 31 the human pancreatic cancer -derived cell line Panc -1, 32 and the mouse mammary tumor -derived GR cell line 33 were all cultivated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. The human mammary tumor -derived cell lines ZR -75 -1 34 and T47D 35 were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. In addition, the medium for ZR -75-1 cells contained 5 g/mL insulin. MCF -7 cells, also derived from a human mammary tumor, 36 were cultivated in MEM with nonessential amino acids and 10% fetal bovine serum. To induce expression from the WAP promoter, cells were given in addition to the growth medium, 5 g /mL insulin, 5 g /mL prolactin, and 10 À 6 M dexamethasone every 3 days.
Transfections and infections
The retroviral packaging cell line PA317 29 was transfected with the WAP ProCon vector plasmid, and stable populations of transfected cells were selected in DMEM supplemented with 10% fetal bovine serum and 400 g /mL G418 as previously described. 37 The cell culture medium from these cells was used as a source of virus to infect target cells as previously described. 37 
PCR analysis of ProCon
Genomic DNA was prepared from CrFK, T47D, and MCF -7 cells. PCR was performed using the following primers: P1 ( 5 0 -AGATGTAGCCACGAACTC -3 0 ), specific for the WAP 5 0 sequences; P2 (5 0 -TTCATCCACCACATACA-GGC -3 0 ), specific for the -gal gene; P3 ( 5 0 -GTG-TGGCCAAGAAGGAAGTG -3 0 ), specific for the WAP central region; and P4 ( 5 0 -GCGCCAGTCCTCCGATT-GA -3 0 ), specific for the R region. The PCR products were hybridized either with a 32 P -labeled 320 -bp XhoI/XbaI WAP -specific DNA fragment or with an MLV-specific PCR product as previously described. 21 Recloning WAP -ProCon proviruses from transduced cells and sequencing Genomic DNA was isolated from a population of CrFKtransduced cells and digested with the restriction enzyme BspHI, which does not cleave within the vector provirus. The DNA fragment was self -ligated and used to transform competent DH10 B Escherichia coli by electroporation. Successfully transformed bacteria were selected on agar containing kanamycin (30 g/ mL ) plates, resistance being conferred by expression of the neomycin resistance gene. Only DNA fragments carrying retroviral vector sequences containing the origin of replication can confer resistance to the kanamycin. Recloned proviruses were sequenced using 1 g of plasmid DNA and 10 pmol of one of the following primers: (a ) a MLV-R region -specific primer (mlvrcom: 5 0 -AGTCAATCGGAGGACTG -3 0 ); (b ) a primer spanning the R /U5 region of MLV ( mlvrcom2: 5 0 -CCACAAGT-CGGATGCAACTG -3 0 ); or (c ) a WAP -specific primer ( wapanfc: 5 0 -AGTTCGTGGCTACATCTGAG -3 0 ). Sequencing was carried out using an automatic sequencer ( ABI 373a; Applied Biosystems ). The reactions were performed using a dye terminator cycle sequencing kit according to the manufacturer's instructions ( Applied Biosystems ).
Northern blot analyses
RNA was prepared from transduced cells and tumors as described previously. 38 Aliquots of total RNA ( 20 g ) were separated on a 1% denaturing formaldehyde gel and transferred to a Zeta -Probe membrane. The RNA was hybridized either to a 32 P-labeled 0.4 -kb MluI -galspecific probe generated from pBAG, or to a 32 P -labeled 1.2-kb PstI -actin-specific probe.
Assay for -gal activity
Cell extracts were prepared and a quantitative chemiluminescent assay for -gal employed, as previously described, 39 using the Galacto -Light kit (Tropix, Bedford, MA ) according to the manufacturer's instructions.
Results
A proximal WAP promoter fragment directs mammary expression
An expression construct carrying the proximal promoter region in a 405-bp fragment of the murine WAP promoter was linked to the hGH gene. This expression construct ( WAP3 -hGH ) was used to generate transgenic mice. Southern blot analysis of DNA from two independent lines is shown in Figure 2A . Densitometric scanning of the lanes revealed that line 53 /33 (lane 1) carries an estimated copy number of around 71, whereas line 54 /9 ( lane 2) carries around 155 copies of the WAP3 -hGH transgene in a concatameric form ( each copy being 5.9 kb). Additional bands (Fig 2, lanes 1 and 2 ) represent chimeric transgene -flanking mouse DNA at the borders of the concatamer.
In order to determine whether the proximal WAP promoter fragment retains mammary specificity, different organs of the transgenic mice were analyzed for expression of the WAP3 -hGH construct. Using a sensitive RT-PCR with primers located in exons 2 and 5 of the hGH reporter gene ( Fig 2B ) , a characteristic product of 518 bp was expected to be amplified from RNA isolated from organs in which the WAP promoter was active. Whilst no signals could be observed in nontransgenic mice ( Fig 2B, lanes 1-8 ) , clear signals were seen using RNA from a representative WAP3 -hGH transgenic mammary gland (lane 5 ) and cerebellum ( lane 7) but not other organs. The integrity of the RNA and the ability of this RNA to be amplified by RT-PCR was demonstrated by the use of primers specific for the murine glyceraldehyde -3 -phosphate dehydrogenase (GAPDH ) RNA. An RT-PCR product of 690 bp specific for GAPDH was clearly observed in all lanes. Similar results were obtained in all analyzed transgenic animals. Cerebellum -specific expression from a WAP -hGH transgene carrying a 2.4-kb WAP promoter fragment (WAP2 -hGH ) has been previously observed 14 ( see Discussion ). To ensure the presence and quality of amplifiable mRNA, the primers gap and gapc were used to amplify a 690 -bp fragment of GAPDH RNA. C: Real -time TaqMan 1 RT -PCR analysis of the relative levels of expression of hGH found in the mammary glands for six lactating mice transgenic for either WAP2 -hGH or WAP3 -hGH. The expression level of the WAP -2 and WAP -3 promoters was estimated using the comparative C T method ( Applied Biosystems User Bulletin No. 2: ABI Prism 7700 Sequence Detection System ). The calculated relative expression levels are shown above each column.
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In order to compare transgene expression levels in the mammary glands of WAP3 -hGH mice as compared to WAP2 -hGH mice, 14 real -time PCR analyses were performed on RNA from lactating mice using primers specific for the hGH transgene. The hGH expression per sample was normalized to the amount of cells using a second real -time PCR specific for rRNA and expressed as relative expression units (see Materials and Methods ). As shown Figure 2C , although animal -to -animal variation was seen among the six tested mice of WAP2 -hGH and WAP3 -hGH transgenics, the average expression level was similar ( mean relative expression of 105.5 for WAP2 -hGH mice compared to 103 for WAP3 -hGH ).
A WAP -carrying ProCon retroviral vector
To determine whether the WAP3 region of the WAP promoter is also able to direct expression in mammary tumors, it was inserted in place of the U3 region of the 3 0 LTR of a MLV-based ProCon vector (Fig 3A, open box) . After transduction of cells, RT, and integration of the ProCon vector proviral DNA, the WAP promoter is expected to replace the viral promoter. 20, 21 The pWAP -ProCon vector and the parental pBAG vector plasmid, both of which carry an internal neomycin resistance gene constitutively expressed from an SV40 promoter ( Fig  3A ) , were introduced into the amphotropic packaging cell line PA317 29 and the resultant retroviral vector particles used to transduce a number of cell lines. The titer of virus obtained from a population of WAP -ProCon vector virus -producing cells was 4.6Â10 3 compared to 6.6Â10 3 from a population of the parental BAG vector-producing cells. In our hands, BAG -derived vectors give titers that are lower than those obtained with later generation vectors such as LXSN, 40, 41 but were chosen because they allow the facile recloning of integrated proviruses ( see below ).
To confirm that the transduced cells had acquired the vector constructs after neomycin selection, and to verify that the WAP promoter sequences were now present in the correct configuration in the 5 0 LTR of the vector provirus, DNA was prepared from nontransduced and transduced cell populations of CrFK, T47D, and MCF -7 cells and analyzed by PCR. Primers specific for either the WAP promoter (Fig 3A: P1, P3 ) or MLV-R sequences ( P4), in combination with a second primer complementary to the -gal gene (P2 ),which is present in all three constructs, were used for these analyses. The PCR products were hybridized to a WAP - 8, and 14 ) , MCF -7 ( lanes 4, 10, and 16 ), and CRFK ( lanes 6, 12, and 18 ) cells was amplified by PCR using primers specific for the WAP -U3 region: P1 ( lanes 1 -6 ), P3 ( lanes 7 -12 ) , or MLV -R sequences: P4 ( lanes 13 -17 ) , together with a primer specific for the -gal gene ( P2 ). The PCR product was separated on an agarose gel, transferred to a Zeta -Probe membrane, and hybridized to a WAP ( I ) -or MLV ( II ) -specific probe. C: Sequence analysis of the WAP / MLV junction from recloned provirus after promoter conversion. Shown are the sequences at the U3 -R and the integration site -U3 junctions in the 5 0 LTR. Small letters indicate flanking host cell sequences at the site of integration; capital letters WAP ( nonitalics ) and MLV -R region ( italics ) vector sequences reveal that ( a ) the border between the WAP -U3 and MLV -R regions is intact after ProCon; and ( b ) the inverted repeated ( IR ) has been used for integration. The SacII and MluI restriction enzyme cleavage sites originally used to insert the WAP promoter are shown, as is the transcription initiation site ( + 1 ).
Cancer Gene Therapy WAP promoter targets human mammary tumor cells F Ö ztü rk -Winder et al specific (Fragment A ) or to an MLV-specific ( Fragment B ) 32 P -labeled DNA fragment (Fig 3, A and B ) . DNA prepared from cells infected with the WAP -ProCon vector gave PCR products of 2.4 and 2.1 kb after amplification using the P1 /P2 and P3 /P2 primer pairs, respectively. These products hybridize, as expected, to both the WAP -( Fig 3B: panel I; lanes, 1, 3 , 5, 7, 9, and 11 ) and MLV- (Fig 3B: panel II; lane, 1, 3 , 5, 7, 9, and 11 ) specific hybridization probes. In contrast, the primer pair P4 / P2 gave a PCR product of 1.8 kb that only hybridized to the MLV probe ( Fig 3B: panel II; lane, 13, 15, and 17 ) , but not to the WAP probe ( Fig 3B: panel I; lanes, 13, 15, and 17 ) . Taken together, these data suggest that promoter conversion has occurred as expected.
The WAP ProCon vector carries a prokaryotic origin of replication ( Fig 3A ) , allowing the recloning of the integrated provirus form genomic DNA. 26 Genomic DNA was isolated from the population of transduced CrFK cells, digested with the restriction enzyme BspHI, which cleaves outside of the vector provirus, giving rise to integration -specific DNA fragments. The cleaved DNA was ligated and used for electroporation of E. coli. After selection on kanamycin, a number of plasmids were obtained and analyzed. Sequencing of the junction between the host cell DNA flanking sequence and the 5 0 end of the provirus revealed that the SacII restriction site and the WAP U3 sequences inserted into this site are intact as expected (Fig 3C ) . The MLV inverted repeat was also present, but had been shortened by 2 bp, relative to the original vector plasmid. This was expected due to the processing of the ends of the proviral molecule during the integration event. 42 Similarly, the sequence at the border between the WAP -U3 and MLV-R regions in the 5 0 LTR revealed that the WAP -U3, MluI restriction site, and MLV-R sequence were also intact ( Fig 3C ) .
WAP3 promoter -driven expression in transduced mouse and human tumor cells
Expression from the WAP promoter is tightly regulated, the major site of expression being in mammary cells. In order to obtain expression of WAP from cells in culture, the cells must be grown in matrices such as collagen or matrigel. 43 To determine the expression pattern from the WAP promoter in the context of the MLV-based vector, RNA was prepared from the infected cell populations and used for Northern blotting. Genomic length transcripts of 7 kb, hybridizing to the -gal gene, could be detected in all three transduced human mammary epithelial cell lines analyzed (Fig 4A; ZR -75 The use of -gal as a marker gene allows a more quantitative estimate of promoter activity through the enzymatic activity that can be determined in transduced cells using a light -emitting substrate in a photometric assay. A number of cell lines transduced either with the WAPProCon vector or the parental BAG vector were investigated. The levels of expression from the WAP promoter (black bars ) in human mammary tumor -derived cell lines were similar to ( MCF -7, ZR -75 -1 ), or two to three times higher than (T47D ), the activity of the MLV promoter ( BAGshaded bars ) in the same retroviral backbone ( Fig 4B ) . However, importantly, although the MLV promoter showed good expression in human bladder carcinoma ( EJ ), feline kidney ( CrFK ), and mouse fibroblast (NIH /3T3 ) cells, no expression could be measured from the WAP promoter in these cells, underscoring the mammary specificity of the promoter. Surprisingly, the normally ubiquitously active MLV promoter was not active in pancreatic tumor cells ( Fig  4B; Panc 1 ).
WAP -3 promoter -mediated expression in transduced human tumor cells implanted in mice
In view of the encouraging results suggesting breast tumor specificity of the WAP promoter in vitro, we were interested whether this specificity would be maintained in vivo. To this end, transduced human mammary and Cancer Gene Therapy WAP promoter targets human mammary tumor cells F Ö ztü rk -Winder et al nonmammary -derived tumor cell lines were transplanted into the mammary fat pad of SCID /beige mice. The cell lines quickly formed tumors, which were allowed to grow in vivo for 7 -10 weeks before being explanted and analyzed. Northern blot analysis of RNA prepared from these tumors ( Fig 5A ) confirmed the previous in vitro findings. Whereas the MLV promoter ( BAG ) was active in tumors arising from all three human mammary tumor cells ( ZR -75-1, lane 6; T47D, lane 7; MCF -7, lane 8 ) and particularly strongly active in a tumor arising from the bladder carcinoma cells ( EJ, lane 9), the WAP promoter was only active in tumors derived from the three human mammary tumor cell lines ( lanes 1, 2, and 3) . Again, neither promoter was active in the pancreatic tumor cell line (lanes 5 and 10 ).
The levels of this in vivo expression were quantified by analyzing protein extracts from the tumors for -gal enzymatic activity. In contrast to the previous in vitro findings, clearly higher expression was detected from the WAP promoter (black bars ) than from the MLV promoter ( shaded bars ) in the three independent human mammary tumor cells ( Fig 5B ) . No expression was detected from either promoter in the bladder carcinoma or pancreatic tumor cells.
Discussion
The WAP promoter was originally cloned from the genome of rodents and has been used in various transgenes to direct expression of linked sequences preferentially to the mammary gland of pregnant and lactating mice and mammary tumors. 3 A number of factors have been identified, which bind to defined elements in the WAP promoter, and these cooperative interactions seem to be required to confer mammary specificity. 44 We have previously shown that transgenic mice harboring either a 2.4 -kb mouse WAP promoter fragment (WAP2 ) containing both proximal and distal promoter elements, as well those harboring a minimal ( 92 bp) mouse WAP promoter fragment ( WAP1 ), carrying only part of the proximal promoter ( Fig 1 ) , show mammary-specific expression.
14 However, the level and duration of expression are severely compromised in the minimal promoter transgenics. In contrast, Li and Rosen 8 have shown that mutation of only one of two NF1 sites or the GAS element in the distal region of the rat WAP promoter is enough to severely affect or even abolish expression. Here we show that a 405-bp fragment (WAP3 ) containing only the proximal region of the mouse WAP promoter is sufficient to direct pregnancydependent expression of a coupled gene in transgenic mice. Further, the expression level of the linked transgene, measured by sensitive real -time TaqMan 1 PCR, seems to be about the same for both the long 2.4 -kb WAP promoter ( WAP2 ) and for the intermediate 405-bp WAP promoter ( WAP3 ). The interpretation of these findings may, however, be more complex because a negative regulatory element ( NRE ) located between the proximal and distal regions ( À 93 to À 411 ) limits expression from this promoter in cell culture 22 and a factor binding to this NRE has been characterized. 22, 23 This NRE may contribute to the suppression of expression in nonmammary organs. In this light, it is interesting that the NRE is present in all of the constructs used by Li and Rosen, 11 as well as in the WAP2 14 and WAP3 constructs used here that show mammaryspecific expression.
We have previously reported that the transgenic mice carrying the WAP2 -hGH construct show, in addition to mammary -specific expression, a specific expression in the Purkinje cells of the cerebellum. Because a number of transgenic lines showed cerebellum -specific expression, this expression specificity is unlikely to have resulted from site of integration effects.
14 Other groups have reported similar ectopic brain expression specifically from WAP promotercarrying transgenes. 45 -47 Brain specificity seems to depend on the artificial combination of the WAP promoter and the coding sequences of the transgene: À hGH 14,46,47 and urokinase -type plasminogen activator 45 giving ectopic expression, whereas other coding sequences apparently do not.
14 Our previous studies tentatively defined the region of the WAP promoter that confers this ectopic brain -specific expression in combination with hGH to À 24,000 and À 92 bp relative to the WAP transcription initiation site.
14 In order to be able to compare our results with our previous data, we decided to utilize the same hGH reporter gene in the study reported in this manuscript. Interestingly, the WAP3 -hGH construct also resulted in both brain -and mammary -specific expression, further delimiting the sequences of the WAP promoter involved in a region located between À 405 and À 92. Although such expression is undesirable for expression targeting, the use of this WAP fragment in an MLV-based retroviral vector designed to specifically deliver a therapeutic gene to the mammary gland / tumors is unlikely to infect cells of the brain because the vector would have to cross the blood -brain barrier and infect nondividing cells. Concerning the latter, MLV is unable to efficiently infect nondividing cells. 48 The ability of a smaller fragment of the WAP promoter to direct mammary expression raised the possibility of inserting this fragment (proximal promoter and NRE ) into a retroviral vector in such a way as to replace the retroviral promoter with the WAP promoter in transduced cells. Such a vector may be useful for mammary-specific expression of genes. Because we show here additionally that the endogenous WAP promoter is activated in a significant number of primary rodent mammary tumors (Fig 3 ) , this also raises the possibility that the promoter and, in particular, the WAP3 fragment used here would be active in human mammary tumor cells for potential use in gene therapies.
We were able to demonstrate that this fragment is indeed able to direct heterologous gene expression in retroviral vector -transduced human mammary tumor -derived cell lines in culture, but not in human tumor cells of other origin. This is unlikely to be an artifact of cell culture because three independently established, human mammary tumor -derived cell lines showed similar expression. As has been previously observed for the WAP promoter, expression in the retroviral context still requires an intact three -dimensional structure 43 and pregnancy hormones, suggesting that similar mechanisms of expression control may be involved in the murine and human mammary tumors. Promoter activity in the human mammary tumor cell lines was not necessarily to be expected, particularly because a human WAP homolog has yet to be identified. Nevertheless, it seemed likely that the underlying regulatory mechanisms controlling the expression of many, if not all, milk genes are similar and conserved among mammals.
The tissue specificity of the proximal WAP promoter plus NRE for mammary tumors was much more evident when the transduced human tumor cells were reintroduced into the mammary fat pad of SCID mice. In this more physiological situation, the WAP promoter was consistently more active than the promiscuous MLV promoter and was limited to expression in human tumors of mammary origin. These data suggest that it may be advisable in the future to test tissue specificity in vivo using similar reimplantation approaches, rather than relying on in vitro cell culture.
The ability of the WAP promoter to function in the context of a retroviral vector is of interest for potential use to drive therapeutic gene expression in gene therapy strategies directed against breast cancer. Such genes could include those encoding toxic products, for example, the diphtheria toxin gene or, alternatively, suicide genes, allowing druginduced cell death of transduced cells and, due to bystander activity, cells in the vicinity. Two such suicide genes have recently shown promise as potent antimammary tumor principles. 49 
